Bittium and Cerenion announce collaboration on bringing next-generation brain monitoring to intensive care

Oulu, Finland, May 30, 2018 – Bittium BioSignals Ltd, a subsidiary of Bittium Corporation, and Cerenion Oy announce a collaboration project on bringing advanced brain monitoring into the array of vital signs monitoring available to intensive care staff. The collaboration aims on providing a comprehensive solution for brain electrical activity monitoring for intensive care patients, by combining Bittium BrainStatus™ a wireless EEG-monitoring device meant for real-time brain electrical activity to Cerenion’s innovative C-Trend™ index that interprets EEG signal to a simple score facilitate and accelerate the work of nursing staff.
Recently European CE medical approved wireless Bittium BrainStatus™ EEG amplifier and electrode headband enables high quality and fast EEG signal measurement. Through the use of Cerenion C-Trend™ technology this signal data is turned into a simple score that reveals the status of the patient’s brain at the bed-side and without requiring any changes to the care of the patient.
"Based on advanced machine learning algorithms and artificial intelligence, the Cerenion C-Trend index transforms the standard EEG signal set into a practical score that is readily interpretable by intensive care staff", reports Dr. Timo Koskela, CEO of Cerenion Oy. "The C-Trend index coupled with Bittium’s easy-to-use wireless hardware is a perfect match", he continues.
"The easy to wear, wireless and compact Bittium BrainStatus EEG amplifier and electrode headband enables quick measurement up to 24 hours. The EEG measurement score transformed by the Cerenion C-Trend technology makes the interpretation of the measurement easy. This is a functional and easy-to-use solution for the intensive care unit and speeds up the patient’s treatment process", says Hannu Huttunen, CEO of Bittium Corporation.
The first line of C-Trend-enabled Bittium BrainStatus devices are expected to become available in 2019.
Further information:
Dr. Timo Koskela, CEO
Tel. +358 40 5773 706
Bittium specializes in the development of reliable, secure communications and connectivity solutions leveraging its 30 year legacy of expertise in advanced radio communication technologies. Bittium provides innovative products and services, customized solutions based on its product platforms and R&D services. Complementing its communications and connectivity solutions, Bittium offers proven information security solutions for mobile devices and portable computers. Bittium also provides healthcare technology products and services for biosignal measuring in the areas of cardiology, neurology, rehabilitation, occupational health and sports medicine. Net sales in 2017 were EUR 51.6 million. Bittium is listed on Nasdaq Helsinki. http://www.bittium.com
Cerenion Oy develops the world’s first practical method for measuring the brain function of intensive care patients. Cerenion C-Trend™ technology (pat. pend.) aims to reveal the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The solution works by combining standard EEG-measurement with advanced machine learning algorithms and artificial intelligence. The technology has the potential of improving both the quality and the cost of intensive care. http://www.cerenion.com
Visit us
Contact us
Cerenion Oy has received support from the European Regional Development Fund of the European Union.
Cerenion Oy
Elektroniikkatie 3
90590 Oulu
Cerenion Oy
Firdonkatu 2 T 63
00520 Helsinki
Call us: +358 50 447 4909
E-mail us:
This website and all of the content therein is for reference purposes only and is not intended to substitute for advice from a licensed healthcare professional. Not available in the United States. Cerenion™, Cerenion C-Trend™, C-Trend™, "The next-generation brain monitoring company"™ and "The pulse of the brain"™ are registered trademarks and/or trademarks of Cerenion Oy. Cerenion C-Trend™ is intended for use by qualified medical practitioners who will exercise professional judgment in its use. Cerenion technology is protected by Intellectual Property Rights. Patents pending worldwide. All rights reserved. © Cerenion Oy 2020.
Powered by:MetaVisual CMSMobile versionDesktop versionLog in© 2017 - 2021 Cerenion Oy